F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

MD Healthcare, Inc. is engaged in developing innovative precision medical solutions based on micro biome data. The company was founded in January, 2014 and is headquartered in Seoul, South Korea.

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

JB Therapeutics is a clinical stage biopharmaceutical company developing the first new class of analgesic agents in two decades. Their lead compound, JBT-101, is a potent CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is currently being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.

Future Medicine Co., Ltd. engages in providing drug development services in the areas of anti- inflammation, fibrosis, anti virus and anti cancer. The company was founded on June 4, 2015 and is headquartered in Seongnam-si, South Korea.

BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 55 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. “Caring for your Health” is the Group’s motto, and strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. BIAL has launched eslicarbazepine acetate, an epilepsy drug, already available in the US and in several European countries. BIAL has also developed a Parkinson’s disease compound, opicapone, also commercialized in Europe. The company expects to introduce new medicines to the market over the next few years, strengthening its international presence.

Phanes Therapeutics, Inc. is an American company located in San Diego, CA. The firm operates as a biotechnology company. It was founded in 2016 by Ming Wang, he has been the CEO since that date.\nThe company says this about itself: Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it has three assets at clinical stage, including its best-in-class monoclonal antibody (mAb) program, PT199, and two first-in-class bispecific antibody programs, PT886 and PT217. Both PT886 and PT217 have been granted orphan drug designation by FDA. Its pipeline also includes humanized mAbs, biparatopics, and single-chain variable fragments (scFvs) against multiple tumor-associated antigens (TAAs) that are suitable for ADC and CAR-T applications, respectively. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody™, SPECpair™ and ATACCbody™ to develop novel biologics that address high unmet medical needs in cancer. PACbody™, is a proprietary approach for constructing bispecific antibodies without using protein engineering so that the antibody molecules maintain native structures with superb CMC characteristics.

Shuguang Hospital is a private company headquartered in Shanghai, China, that operates as a hospital.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Wuhan Guangxing Scientific Research Co., Ltd., established on 2018-04-28, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);New material technology research and development(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

West China Second University Hospital is a Chinese private company located in Chengdu. The firm provides women and children healthcare services.

Chengdu Benokecheng Biotechnology Co., Ltd., established on 2019-02-28, The scope of business includes the research and development of biological reagents and the provision of technical consultation,technology transfer;Medical Technology Consulting(Does not include health care activities),technology transfer;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Chengdu Genomeer Biotechnology Co., Ltd., established on 2017-08-28, Business scope includes medical research and experimental development;R&D and technology transfer of biological agents,technical consulting;Biotechnology Testing Services;Medical device research and development;Research and development of daily chemical products;Import and export of goods and technology;Sales:Biotechnology Experimental Reagents,Biotechnology experiment consumables(The above range does not include national laws,Administrative regulations,Items restricted or prohibited by the State Council,Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Dong-A Pharmaceutical Co., Ltd., a subsidiary of Dong-A Socio Holdings Co., Ltd., is a company headquartered in Seoul, the South Korea, that manufactures drug products.

Part of Cosmo Pharmaceuticals NV, Cosmo Technologies Ltd. is an Irish company located in Dublin that manufactures and distributes pharmaceutical products. Salix Pharmaceuticals Ltd., now part of Bausch Health Cos., Inc. acquired Cosmo Technologies Ltd. from Cosmo Pharmaceuticals SA.\nThe company says this about itself: COSMO designs, manufactures and markets family-safe technology products. Committed to the idea that technology should be designed for families, not just repurposed from other segments, COSMO is pioneering new product categories. At the center of its offerings is its mobile application, COSMO: Mission Control. This hub for managing connected devices and family software is meant for families who are seeking a new way of doing technology.